Page 57 - Read Online

Casadei et al. J Cancer Metastasis Treat 2022;8:21 https://dx.doi.org/10.20517/2394-4722.2022.05 Page 19 of 19

91. Serrat N, Guerrero-Hernández M, Matas-Céspedes A, et al. PI3Kδ inhibition reshapes follicular lymphoma-immune
microenvironment cross talk and unleashes the activity of venetoclax. Blood Adv 2020;4:4217-31. DOI PubMed PMC
92. Zinzani PL, Flinn IW, Yuen SLS, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in
relapsed/refractory follicular lymphoma. Blood 2020;136:2628-37. DOI PubMed PMC
93. Li D, Poon KA, Yu SF, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment
for non-Hodgkin lymphoma. Mol Cancer Ther 2013;12:1255-65. DOI PubMed
94. Palanca-wessels MCA, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab
vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol
2015;16:704-15. DOI PubMed
95. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or
refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 2019;6:e254-65.
DOI PubMed
96. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a
multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790-800. DOI PubMed
97. Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell
non-Hodgkin lymphoma. Blood 2021;137:2634-45. DOI PubMed PMC
98. Jacobson C, Chavez JC, Sehgal AR, et al. Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in
Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood 2020;136:40-1. DOI
99. Hirayama VA, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell
immunotherapy. Blood 2019;134:636-40. DOI PubMed PMC
100. Schuster SJ. Bispecific antibodies for the treatment of lymphomas: Promises and challenges. Hematol Oncol 2021;39 Suppl 1:113-6.
DOI PubMed
101. Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable,
Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T
Therapy. Blood 2020;136:42-3. DOI
102. Budde LE, Assouline S, Sehn LH, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With
Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol 2022;40:481-91. DOI PubMed PMC
103. Bartlett NL, Giri P, Budde LE, et al. Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable
and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II
Study. Blood 2021;138:3573-3573. DOI
104. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell
non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 2021;398:1157-69. DOI PubMed
105. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific
Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol
2021;39:1959-70. DOI PubMed PMC
106. Advani R, Flinn I, Popplewell L, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. N Engl J Med
2018;379:1711-21. DOI PubMed PMC
107. Budde LE, Olszewski, AJ, Assouline S, et al. Mozunetuzumab plus polatuzumab vedotin has promising efficacy and a favorable
safety profile in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: updated results from a phase Ib/II study.
Abstract #533. Presented at the 2021 ASH Annual Meeting, December 12, 2021.